Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Axsome Therapeutics (AXSM) PT Raised to $230 at B.Riley
January 2, 2026 9:37 AM ESTB.Riley analyst Madison El-Saadi raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $230.00 (from $184.00) while maintaining a Buy rating.
... MoreBaird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'
December 31, 2025 1:54 PM ESTBaird analyst Joel Beatty reiterated an Outperform rating and $157.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst comments "Incrementally positive on regulatory updates. Axsome announced two New Year's Eve regulatory updates, with their sNDA for AXS-05 (Auvelity) in Alzheimer's agitation... More
Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
December 31, 2025 1:20 PM ESTLeerink Partners analyst Marc Goodman reiterated an Outperform rating and $150.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst comments "This is very positive news for Axsome, as Alzheimer's disease agitation (AD-A) is a key additional indication to drive... More
